Providers

Full team coverage from the European Hematology Association 2023 Hybrid Congress, which took place June 8-11 in Frankfurt, Germany.

Researchers determined that the Huber et al. criteria regarding prostate-specific antigen (PSA) levels may more accurately predict the need for additional treatment or the possibility of treatment failure compared with other PSA-based definitions.

In this multicenter cohort study, COVID-19 vaccination at any gestational stage improved antibody responses for pregnant individuals and their infants. Booster vaccine recipients demonstrated increased benefits in these effects at delivery.

The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.

A small study suggests the use of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with mantle cell lymphoma (MCL) with secondary central nervous system (CNS) involvement is safe and effective.

Coverage from the June 8, 2023, Institute for Value-Based Medicine session in Austin, Texas, held in partnership with Texas Oncology.

Researchers analyzed numerous biomarkers in patients at risk for inflammatory arthritis to develop measurable scores indicating a patient's vulnerability to disease progression.

New research demonstrated varying trends in early-onset cancer incidence based on race, sex, age, and cancer type.

Greater attention needs to be on educating patients who are switching from a reference product they are successful on to a biosimilar than a patient who is starting a treatment with a biosimilar at the beginning of their disease journey, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.

Data on 10 social determinants of health (SDOH) were analyzed to determine their distribution among low-income patients hospitalized for heart failure (HF) at a safety-net hospital.

The Panicos are on a mission to change how we think about gout. Why? As a husband-and-wife DO duo, the Panicos each have a unique perspective on gout and how physicians in their respective fields can better collaborate to help patients who live with this systemic disease.

The presence of sex differences in immunological functioning influences hidradenitis suppurativa (HS).

New research suggests that measuring the inflammatory marker myeloperoxidase (MPO) may be an effective strategy for the prediction of patients' risk of mortality in a myriad of cardiac—and potentially non-cardiac—diseases.

Findings from a retrospective analysis suggest an association between bridging therapy and poorer outcomes among patients with aggressive, relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).

New biomarker technology shows promising results for predicting the prognosis of patients with prostate cancer after radical prostatectomy.

New research found that ovarian cancer risk is reduced by salpingectomy just as much as by tubal ligation, contradicting guidelines that suggest otherwise.

Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.

Study authors investigated the effect of physical activity as a modifiable risk factor among individuals living with high-risk hypertension in this subanalysis of data from the Systolic Blood Pressure Intervention Trial (SPRINT).

The overall burden of aging-related comorbidities was higher in women compared with men, especially in people living with HIV.

According to one panelist, the leading causes of hypoglycemia in older adults are insufficient nutrition and taking the wrong dose or type of insulin, both of which can be addressed at the patient and system level.

Anthracyclines are widely used to treat hematological and solid-tumor cancers, but past research suggests their use may be associated with late cardiac effects, including heart failure, among patients with lymphomas and other cancers.

While there is currently no effective treatment for chemotherapy-induced peripheral neuropathy, one of the most common and severe adverse effects for patients who have undergone chemotherapy for ovarian cancer, a 6-month aerobic exercise intervention significantly improved symptoms.

Study authors used data from the Taiwan National Healthcare Insurance Research database and Death Registry for their population-based retrospective cohort study.

The pain and impact of sickle cell disease (SCD) was associated with patient social and emotional functioning in a recent study.

New research shows that in vitro fertilization with or without intracytoplasmic sperm injection and the use of fresh or frozen embryo transfers were not associated with an increased risk of cardiovascular disease (CVD) for the mother.

Survey responses revealed the rates and times at which patients switched from oral to biologic therapies.

Polymyalgia rheumatica (PMR) is an inflammatory disease often misdiagnosed as certain cancers, among other diseases. Researchers have recently made progress to better diagnose PMR using a standard uptake value index based on fluorodeoxyglucose with positron-emission tomography/computed tomography.

A global assessment found that there was a high prevalence of chronic pain in women living with HIV.

Among 2.5 million adults with opioid use disorder (OUD), only 36% received any substance use treatment, and only 22% received medications for OUD in a recent study.